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Ketamine has been in clinical use for over half a century, yet its precise mechanisms of action remain
mysterious for the large part. Its hypnotic effects appear to be largely mediated by blockade of NMDA and
HCN1 receptors, but cholinergic, aminergic, and opioid systems appear to play both a positive and
negative modulatory role in both sedation and analgesia. Ketamine’s effects in chronic pain, and as an
antidepressant, far outlast the actual drug levels, and are probably mediated by a secondary increase in
structural synaptic connectivity that is mediated by a neuronal response to the ketamine-induced hyper-
glutamatergic state.
 2014 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Ketamine is awell-established anaesthetic drug that has been in
use for around 50 years.1 It produces a spectrum of anaesthetic
effects that results in a type of anaesthesia that has an obviously
different feel qualitatively as compared tomore traditional volatile-
based anaesthesia. This state of so-called “dissociative anaesthesia”
has beenwell described as including: (a) hypnosisewhich includes
psychotomimetic effects at low concentrations, followed by in-
creasing sedation and unconsciousness at higher doses; (b) intense
analgesia (or more accurately anti-nociception); (c) increased
sympathetic activity; and (d) maintenance of airway tone and
respiration. It has been known since the mid 1980s that ketamine
caused use-dependent blockade of the N-methyl-D-aspartate
(NMDA) receptor2; and that this blockade of excitatory synaptic
activity probably caused the loss of responsiveness that is associ-
ated with clinical ketamine anaesthesia. However, in the inter-
vening years, subsequent work has demonstrated that ketamine
exhibits a wide range of different molecular effects, and its clinical
usefulness has expanded to include a role in the management of a
wide range of conditions including acute and chronic pain,3 and,
most recently, as a rapidly acting antidepressant.4 Intriguingly
many of these clinically beneﬁcial effects seem to occur long after
the actual drug has been almost completely excreted from the body.
Clearly the relationship between the drug’s binding and its clinical
effects is more complex than ﬁrst realised.z (J. Sleigh).
 BY-NC-ND license.Linking observed molecular actions for any particular drug with
its clinical effects is an abiding pharmacological problem. We
would propose that the following set of axioms can be used as a
guide to decide whether a particular mechanism is a necessary and
sufﬁcient cause of an observed behaviour.
1) The molecular or cellular effects occur at a similar concentration
to those which are associated with behavioural changes e and a
reasonable doseeresponse curve should be deﬁned.
2) All the drugs which have been observed to cause a particular
molecular or cellular effect should cause the associated behav-
ioural change. There is a proviso; if some drug has a cellular
effect in the laboratory, but none in vivo, there must be a
reasonable explanation for this discrepancy e such as inability
to penetrate the bloodebrain barrier in sufﬁcient concentra-
tions, or the presence of drugmetabolism or extrusion enzymes.
3) The co-administration of agonists or antagonists should
modulate the doseeresponse curve of the drug. Again there is a
provisoewhich is quite commonwith anaesthetic drugs, which
tend to be allosteric modulators of receptor or ion channel
function. Unless there exists a pure competitive antagonist
compound, it is likely that these effects will be modest.
4) Other non-drug interventions such as genetic (knockout, or
knockin, full or conditional) or mimetic peptides which produce
the same changes in neuronal mechanisms, as are seenwith the
drug, should produce the same behavioural effects as the drug.
Using these principles for guidance, we will brieﬂy summarise
the known molecular effects of ketamine, and then discuss the
relevant importance of each on the known clinical actions of the
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of research, there are still many question marks over exactly which
of the observed molecular actions of ketamine are signiﬁcant in
causing the various observed components of anaesthesia in pa-
tients. The aim of this review is to provide a broad summary of
the information relating to ketamine’s actions and effects. It does
not have the space to touch on the other effects of ketamine on
inﬂammation, apoptosis, or in neuronal excitotoxicity. For further
in-depth reviews, we would draw the readers’ attention to a recent
issue of CNS Neuroscience & Therapeutics that was devoted to
examining the various roles of ketamine in modern medicine.5
2. Molecular actions of ketamine
2.1. Immediate effects
At concentrationswithin the clinical dose range, ketamine is now
knowntodirectlyaffect awiderangeof cellularprocessese including
blockade of NMDA channels, neuronal hyperpolarisation-activated
cationic currents (Ih, also known as hyperpolarisation-activated
cyclic nucleotide channels (HCN1)), nicotinic acetyl-choline ion
channels, delta and mu-opioid agonism and opioid potentiation,6
the nitric-oxide (NO)ecyclic guanosine-mono-phosphate (cGMP)
system, non-NMDA glutamate receptors (a-amino-3-hydroxy-5-
methylisoxazole-4-propionic acid (AMPA)), and metabotropic
glutamate receptors (mGluR), reduction in cholinergic neuro-
modulation,7,8 increased release of aminergic neuromodulators
(dopamineandnoradrenaline),9e11neurosteroids,12 andL-typeCa2þ
channels.13 Of course all these different systems do not act in isola-
tion, but are themselves part of the integrated nervous systemwith a
myriad of interactions occurring at all levels.14
2.2. How does ketamine disrupt NMDA channel function?
At the level of the chemical binding of the NMDA antagonistic
drugwith the NMDA receptor, the exact processes bywhich various
groups of compounds exert an impairment of NMDA receptor
function are quite complex and reviewed in detail in.15e17 There are
numerous known compounds that inﬂuence NMDA action. They
can be broadly classiﬁed as: (a) competitive antagonists, (b) open
channel blockers (ketamine is one of the least potents), (c) non-
competitive antagonists, and (d) allosteric potentiators. All these
compounds have differing relative potency on the different NMDA
receptor subtypes (commonly termed GluN1, GluN2A, GluN2B,
GluN2C, and GluN2D e but also called NR1, NR2A-D) e with
resultant different spectra of action. These subtypes showmarkedly
heterogeneous distributions in the brain, which may account for
the variations in clinical effects caused by different NMDA blocking
compounds. The GluN2A subtype is found throughout the brain,
whereas GluN2B is primarily conﬁned to the limbic system, thal-
amus, and spinal cord, GluN2C to the thalamus and cerebellum, and
GluN2D in the brain stem, diencephalon, and spinal cord.
Another important reason for the variation in effect lies in the
off-rate of the compound. This phenomenon has been termed
“trapping block”.18,19 Compounds with a slow off-rate such as ke-
tamine (86% trapping) and MK-801 (almost 100% trapping) are ex-
amples of high-trapping antagonists. When the glutamate has
dissociated from its binding site on the NMDA receptor, the keta-
mine remains trapped in the, nowclosed, ion channel thus causing a
prolonged tonic blockade which disrupts both physiological and
pathological function. In contrast low-trapping (fast off-rate) an-
tagonists are able to escape from the channel before it closes, thus
allowing some preservation of physiological NMDA function, and
hence fewer side effects. For example the compound memantine
(50e70% trapped) hasminimal sedative or psychotomimetic effects.It is a low afﬁnity open-channel blocker with a fast off-rate. It
therefore only blocks NMDA channels which are open for a patho-
logically prolonged time, and has minimal effect when the NMDA
channel is only transiently open, as occurs in most physiological
states. In many ways this mechanism is analogous to the effect of
persistent sodium channel blocking antiepileptic drugs.20 The net
result is an NMDA blocker without appreciable anaesthetic effects.
2.3. Delayed effects of ketamine
Cell function consists of much more than ion channel function.
Each of the immediate effects of ketamine disrupts a large number
of downstream, and more longer lasting, cellular processes, such as
altered gene expression and protein regulation. Perhaps this is not
surprising, given the pivotal importance of NMDA control of cal-
cium entry into the cell, and the many intracellular effects of cal-
cium ions on protein and mitochondrial function.
Ketamine has been shown to result in suppression of immediate
early gene expression at the site of mechanical injury (zif/268, c-fos,
junB, fosB, c-jun, junD).21 It also alters the regulation of NMDA
receptor1 phosphorylation22 and NMDA receptor1 mRNA expres-
sion23 in rat and mouse models of hyperalgesia, and also limits
astrocytic andmicroglial activation as seen in reduced glial ﬁbrillary
acidic protein (GFAP) expression24,25; effects that correlate with a
reduction in neuropathic pain. While these chronic pain models
reﬂect slowevolving patterns of nociception, similar actionsmay be
relevant to acute pain. Ketamine has also been shown to enhance
brain-derived neurotrophic factor (BDNF) andmammalian target of
rapamycin (mTOR) protein levels in the rat hippocampus,26,27
resulting in modiﬁcation to the number and function of synaptic
connections.
A simple pictorial representation of the effects of ketamine is
showninFig.1.Wewillnowexamineeachclinicaleffect inmoredetail.
3. Psychotomimesis
At ketamine concentrations of around 50e100 ng/ml, most pa-
tients will report feelings of dissociation and even suffer ﬂorid
psychotic symptoms of hallucinations and delirium. These symp-
toms are usually attributed directly to the NMDA blockade, as it is a
prominent feature of most NMDA antagonist compounds. However
there are a small set of NMDA-blocking drugs in which the psy-
chotomimetic effects seem to be curiously minimal. Whilst some of
this may be explicable by differences in the “trapping block” as
described previously, it is likely that other mechanisms contribute
signiﬁcantly to the potential to induce hallucinations.
In recent years it has become clear that ketamine disturbs the
feedback mechanisms that control synaptic homoeostasis e either
bymodifying neurotransmitter release or re-uptake, or background
neuromodulator tone. One interesting possibility is the effect of the
ketamine in reducing the ability of NADPH oxidase (NOX2) to
control glutamate release.28 A relative overabundance of glutamate
activity has been associated with psychosis. However, an alterna-
tive, or perhaps complementary, explanation is that the ketamine
has disturbed ‘Regulator of G protein signalling 4’ (Rgs4); which is a
signal transduction protein that controls the function of mono-
amine, opiate, muscarinic, and other G protein-coupled receptors.29
It is well known that ketamine’s effects in increasing dopaminergic
activity,11 and possibly a net decrease in acetyl choline activity7 will
act together to make delirium more pronounced.
4. Hypnosis
Loss of responsiveness to the outside world occurs at
about twenty-fold higher concentrations (around 2000 ng/ml) of
Fig. 1. Summary diagram of the neuropharmacological actions of ketamine, and the resultant clinical effects. The rapid effects and actions are represented at the top left, and the
more delayed and prolonged effects and actions represented towards the bottom right. [NMDA ¼ N-methyl-D aspartate, HCN1 ¼ hyperpolarisation-activated cyclic nucleotide
channels, ACh ¼ acetyl choline, nACh ¼ nicotinic acetyl-choline receptors, AMPA ¼ a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid, mGluR ¼ metabotropic glutamate
receptors, ERK1/2 ¼ extracellular signal-regulated kinases, NOX ¼ NADPH oxidase, BDNF ¼ brain-derived neurotrophic factor, mTOR ¼ mammalian target of rapamycin,
Rgs4 ¼ regulator of G protein signalling 4, L-type Ca2 ¼ L-type calcium channels, GFAP ¼ glial ﬁbrillary acidic protein].
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fects. Since the elimination half-life of ketamine is around 3 h,30
there is a prolonged period, after anaesthesia, in which the drug
levels are lying in the concentration range that produces psycho-
tomimesis.31 We should also note that the duration of hypnosis
strictly follows the time course of the blood (and effect-site) con-
centrations of the drug; which indicates that secondary slow effects
do not play an important causative role in the hypnosis/anaesthesia
state. Ketamine is unique amongst commonly used anaesthetic
drugs in that it demonstrates a curious mixture of depressant
(such as NMDA antagonism) and analeptic (increase in amines,
glutamate excess, and increased AMPA receptor insertion) molec-
ular actions. For this reason it is hard to achieve full anaesthesia in
many species, and in veterinary anaesthesia, ketamine is commonly
co-administered with an alpha-2 adrenergic agonist to achieve
surgical anaesthesia. It has been suggested that the central nervous
system depression that is seen with ketamine anaesthesia occurs
because the NMDA receptors found on the dendrites of the inhib-
itory neuronal populations are less sensitive to the effects of ke-
tamine than those located on the excitatory neurons. The net result
is that ketamine preferentially inhibits excitatory-to-excitatory
coupling above inhibitory-to-excitatory coupling.32
Although the anaesthesia is commonly attributed to the NMDA
blockade, it is likely that other molecular actions play an important
role in hypnosis. Evidence for this comes from a variety of sources.
Firstly, hypnotic potency does not correlate well with potency for
NMDA blockade. It is clear that many compounds which are much
more potent and are more speciﬁc NMDA blockers e such as
dizocilpine maleate (MK-801) and dextrorphan e are only very
weakly hypnotic.33 One possible explanation for this difference
between ketamine and MK-801, is that ketamine has a relatively
higher potency for GluN2C receptors which would e in theory e
induce relatively more thalamic hyperpolarisation than a drug
which has greater potency on the GluN2A and B receptorse such asMK-801. However the counter example is memantine, which has a
comparable afﬁnity for GluN2C receptors as ketamine, but is not
clinically sedative. Whether this discrepancy can be accounted for
by the marked difference in strength of trapping-block between
ketamine and memantine, is not known.
Secondly, it might be expected that NMDA knockout animals
might be completely resistant to ketamine. Petrenko and co-
workers have studied knockout mice who were deﬁcient in the
GluEpsilon1subchain of the NMDA receptor.34 They found that
these animals were indeed resistant to hypnosis with ketamine.
However these animals were also resistant to a non-NMDA block-
ing anaesthetic agent pentobarbitone e which suggests a non-
speciﬁc analeptic effect in these animals. The authors concluded
that the decreased ketamine sensitivity in the knockout animals
was not caused by the genetic knockout of the NMDA receptor, but
rather, was mediated via a compensatory secondary increase in
monoaminergic tone35 e which would reduce the tendency to-
wards hypnosis.
Recent work has also implicated other families of receptors in
the hypnotic effects of ketamine. In particular, a very clean model e
which used conditional forebrain knock-out mice for the HCN1
channel e showed a 30% reduction in the hypnotic potency of ke-
tamine.36,37 The role of brain stem sleep centres in the hypnotic
actions of ketamine is unclear and somewhat paradoxical.38 The
drug has been shown to promote a slow wave sleep pattern by
decreasing cholinergic activity in the pons.7 In contrast the drug
directly or indirectly augments neocortical aminergic9 and cholin-
ergic39 activity which should promote wakefulness.
5. Analgesia
Ketamine will reduce pain scores in concentrations close to
those that produce psychotomimetic effects (w200 ng/ml). Like the
hypnotic and analeptic effects discussed above, ketamine produces
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place of ketamine analgesia in clinical practice is still subject to
much debate.40,41 There are many conﬂicting data, and the anal-
gesic effects of ketamine have to be carefully interpreted in the light
of speciﬁcally diagnosed pain syndromes.42 It is of note that nor-
ketamine has been shown to actually have anti-analgesic effects,43
and ketamine may actually facilitate endogenous pain pathways44
in some circumstances. The widespread use of the drug is some-
what limited by the narrow therapeutic window between analgesia
and excessive sedation or psychotomimetic effects. In the main, the
analgesic effects are correlated with drug levels e based on direct
receptor mediated analgesia mechanisms. However in the setting
of chronic neuropathic pain syndromes, there is some evidence
for prolonged post-drug analgesia that markedly outlasts the
effective drug levels, which would be mediated by downstream
mechanisms.40,45,46
It is generally considered that supraspinal blockade of the NR2B
NMDA sub-unit has the most important anti-nociceptive inﬂu-
ence47; but ketamine also has direct effects on the delta opioid
receptor, and acts to augment opioid mu-receptor function.48,49
Ketamine certainly modiﬁes responsiveness to opioid receptors.
However its analgesia is not reduced by naloxone; which would
argue against the importance of primary opioid mechanisms of
action. In support of the non-opioid mechanisms of analgesia hy-
pothesis, studies using knockout mice for the G protein-coupled
inwardly rectifying potassium channels (GIRK2s) have suggested
that function of this channel was pivotal in the pathway by which
clonidine and opioids exerted a signiﬁcant part of their analgesia.
In contrast the analgesic effect of ketamine seems to be largely
independent of this pathway50; and rather, the effects were asso-
ciated with increased dopamine activity in these mice. The in-
teractions between ketamine and the opioid system are probably
more relevant in chronic pain, where ketamine reduces opioid
tolerance. In vitro Gupta and colleagues found that ketamine pre-
vented and even reversed opioid mu-receptor desensitisation,
acting downstream of the receptor on the amount of ERK1/2
phosphorylation.51
Ketamine also augments endogenous anti-nociceptive systems
e presumably, in part, via its aminergic (serotonergic and norad-
renergic) activation and inhibition of re-uptake.52 Ketamine also
directly inhibits nitric-oxide synthase which probably contributes
in part to its analgesic effects,53 although the relative importance of
these mechanisms has not been well quantiﬁed to date.
5.1. Control of chronic pain
Ketamine has both acute and prolonged effects on chronic
neuropathic pain syndromes. A single administration of a low anal-
gesicdose (250mg/kg) canrapidly (5e10min)and transiently (2e3h)
reduce ongoing pain of neuropathic origin, as well as symptoms of
allodynia and hyperalgesia.54 The latter may be attributable to a
reduction in NMDA-mediated “wind-up”.55 However, these effects
are not consistent from individual to individual. Even within the
same subject group, transient (<2 h), enduring (6e24 h) and no
analgesic effect may be reported.46 Ketamine applied around the
time of surgery as a single infusion has even been reported to limit
the development of chronic pain 30e180 days postoperatively.56
On the surface, some of these ﬁndings appear to contradict the
clinical observation that ketamine lacks long-lasting analgesic
properties. One explanation is that ketamine’s pre-emptive
reduction in neuropathic pain is a corollary of its antidepressant
effect57,58 d which endures well after the drug has been elimi-
nated.58 Chronic pain and depression are often closely linked,59
although the direction of the causative relationship between the
two is less clear. Alternatively, ketamine may set in chain cellsignalling cascades that interrupt the gradual propagation of
pathophysiological changes associated with chronic pain develop-
ment.60 As outlined in a previous section, ketamine regulates a
number of gene expression pathways potentially linked to chronic
pain aetiology, including NMDA receptor expression, astrocytic
activation and synaptic structure and function. These effects would
long outlast the detectable presence of the drug.
5.2. Antidepressant effects
There has been much recent interest in the use of ketamine as a
‘rapidly acting’ antidepressant. However in this context the time-
of-onset is still around 2 h, and the duration of antidepressant ef-
fect lasts about a week. These effects clearly occur long after the
drug has been eliminated from the body e which is indicative of a
ketamine-induced signalling cascade.61 The putative mechanisms
have been reviewed in detail by Duman and co-workers4; in brief
they suggest that the ketamine at low doses actually increases
glutamate neurotransmission by both increased glutamate release
and increased AMPA receptor expression and insertion into the
synaptic plate. This causes secondary increased BDNF release,
and hence activation of ERK signalling which then stimulates
mammalian target of rapamycin (mTOR) e a kinase that controls
protein translation e and thus via a complex signalling path, leads
to increased synaptic protein expression (GluR1) and increased
insertion and density of synapses e leading to increased structural
connectivity between neurons, particularly in the pre-frontal
cortex.
6. Summary
Apart from its well-knownNMDA blockade, ketamine disturbs a
wide range of intracellular neuronal processes. It seems likely that
the hypnotic effects are caused by a combination of immediate
channel blockade of NMDA and HCN1 channels. In contrast, the
prolonged antidepressant effects probably arise from downstream
“post-drug” effectse such as activity-induced increase in structural
synaptic connectivity. The analgesic effects of ketamine appear to
involve both short term and long term disturbance of cellular
function. Probably its immediate analgesic effects are mediated
predominantly by a combination of opioid system sensitisation and
aminergic anti-nociception, whereas its inhibition of neuropathic
pain relies on a combination of immediate receptor mediated ac-
tion and initiation of longer lasting cell signalling cascades.
7. Outstanding questions
1) To what extent can the analgesic and the sedative components
of ketamine be separated on the basis of their differing neuronal
mechanisms?
2) Would inhibition of the ketamine-induced hyper-glutamatergic
and hyper-aminergic states, improve or worsen the psychoto-
mimesis, analgesia, and hypnosis?
3) How much would direct manipulation of the intracellular sig-
nalling cascades alter the clinical effects of ketamine?Funding
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